Obstetrics & Gynecology Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 2002;99:935-937
© 2002 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eskandari, N.
Right arrow Articles by Greenspoon, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eskandari, N.
Right arrow Articles by Greenspoon, J. S.

CASE REPORTS

Factor VII Deficiency in Pregnancy Treated With Recombinant Factor VIIa

Niloofar Eskandari, MD, Nancy Feldman, MD and Jeffrey S. Greenspoon, MD

Department of Obstetrics and Gynecology, and Division of Hematology and Oncology, Olive View-UCLA Medical Center, Sylmar, California

Address reprint requests to: Niloofar Eskandari, MD, UCLA Medical Center, Department of Obstetrics and Gynecology, 10833 Le Conte Avenue, Los Angeles, CA 90095; E-mail: nilooesk{at}yahoo.com.

ABSTRACT

BACKGROUND: Factor VII deficiency is an autosomal recessive bleeding disorder with an incidence of one in 500,000. Few cases have been reported in pregnancy, and only two patients were treated with recombinant factor VIIa. In the past, fresh frozen plasma or factor VII concentrate has been the conventional treatment for this disorder.

CASE: We report a case of factor VII deficiency diagnosed during pregnancy with a factor VII level of 1%. After prophylactic treatment with recombinant factor VIIa, the patient did not manifest any signs or symptoms of excessive bleeding during labor or postpartum.

CONCLUSION: Given the inherent risks of transmission of human immunodeficiency virus and hepatitis with blood products, recombinant factor VIIa treatment is an alternative that is safe and effective during labor, delivery, and the puerperium.




This article has been cited by other articles:


Home page
 J. Dent. Res.Home page
G. Gomez-Moreno, A. Cutando-Soriano, C. Arana, and C. Scully
Hereditary Blood Coagulation Disorders: Management and Dental Treatment
J. Dent. Res., November 1, 2005; 84(11): 978 - 985.
[Abstract] [Full Text] [PDF]

Home page
 CLIN APPL THROMB HEMOSTHome page
B. Brenner, R. Hoffman, D. Balashov, E. Shutluko, S. Culic, and E. Nizamoutdinova
Control of Bleeding Caused by Thrombocytopenia Associated With Hematologic Malignancy: An Audit of the Clinical Use of Recombinant Activated Factor VII
Clinical and Applied Thrombosis/Hemostasis, October 1, 2005; 11(4): 401 - 410.
[Abstract] [PDF]

Home page
 Obstet GynecolHome page
S. H. Merchant, P. Mathew, T. J. Vanderjagt, T. R. Howdieshell, and K. P. Crookston
Recombinant Factor VIIa in Management of Spontaneous Subcapsular Liver Hematoma Associated With Pregnancy
Obstet. Gynecol., May 1, 2004; 103(5): 1055 - 1058.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
F. W. Bouwmeester, A. R. Jonkhoff, R. H. M. Verheijen, and H. P. van Geijn
Successful Treatment of Life-Threatening Postpartum Hemorrhage With Recombinant Activated Factor VII
Obstet. Gynecol., June 1, 2003; 101(6): 1174 - 1176.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American College of Obstetricians and Gynecologists.